Stimulating Fat Tissue Storage With Niacin to Reduce Fat Accumulation in the Liver.

Summary

Metabolic dysfunction-associated steatotic liver disease (MASLD) (aka non-alcoholic fatty liver disease), commonly occurring in individuals with obesity and type 2 diabetes can lead to liver inflammation/ fibrosis. MASLD results from fat being disproportionately deposited in the liver. The goal of this mechanistic study is to investigate metabolic response in patients aged 50 to 80 years with non-alcoholic fatty liver disease, after niacin (vitamin B3) treatment. The main questions it aims to answer are: * Does Niacin lower the fat deposition in the liver? * Does Niacin raise White Adipose Tissue storage of dietary fatty acids? Researchers will compare Niacin to a placebo (a look-alike substance that contains no drug) to compare the metabolic response. Duration of study per participant: Up to 28 weeks

Eligibility

Inclusion Criteria:

* aged 50 to 80 years;
* diagnosed with MASLD, defined as the presence of liver steatosis + abdominal obesity (as defined by the International Diabetes Federation country/ethnic group-specific criteria;
* all women will be post-menopausal.

Exclusion Criteria:

1. Presence of advanced fibrosis (i.e., ≥ F3 based on liver stiffness \> 10kPa) using vibration-controlled transient elastography (FibroScan), serum ALT \> 3 times the normal upper limit, or signs of portal hypertension \[106-109\].
2. Other hepatic disease.
3. Previous diagnosis of diabetes.
4. Overt cardiovascular or renal disease, cancer (other than non-melanoma skin cancer), or other uncontrolled medical conditions.
5. Any contraindication to MRI.
6. Previous intolerance or allergy to nicotinic acid.
7. Having participated to a research study with exposure to radiation in the last two years before the start of the study.
8. Being allergic to eggs
9. Smoking (\>1 cigarette/day) and/or consumption of \>2 alcoholic beverages per day.

Conditions4

Interventions2

Related trials

• "The Effect of Memantine on the Prevention and Amelioration of Paclitaxel-induced Toxicity in Breast Cancer Patients" — Ain Shams University
• A Study of Cardiovascular Events iN Diabetes Plus — University of Oxford
• Aspirin Continuation or Interruption in Patients at Moderate Risk for Cardiovascular Events Undergoing Colonoscopy and/or Polypectomy — Chinese University of Hong Kong
• Aspirin Use for Gastric Cancer Prevention in the Early Gastric Cancer Patients — National Cancer Center, Korea
• Atorvastatin to Reduce Inflammation After Tuberculosis Treatment Completion — University of Cape Town
• Folic Acid Supplement Versus Placebo for Treating Mucositis Adverse Events in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapy — Niels Fristrup
• Measurement of the Hippocampal Theta Rhythm From the Outer Ear Canal — University of Manitoba
• Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose — Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Browse More Trials